EKIMAS Corporation
ASNB
Other OTC0.85
USD
+0.05
- -
EKIMAS Corporation
ASNB
(Other OTC)
Recent
price
0.85
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- EKIMAS Corporation (OTC: ASNB), now operating as Nordicus Partners Corporation, functions as a U.S. publicly traded business accelerator and holding company focused on Nordic life sciences companies seeking U.S. market entry; it provides corporate finance services including business valuation, growth strategy development, budgeting, investment memoranda preparation, capital raising, reverse takeovers, and facilitation of acquisitions and sales, primarily targeting pharmaceutical, life sciences, and healthcare sectors with emphasis on high-growth areas such as periodontal disease, oral leukoplakia, and central nervous system disorders. The company offers a four-step value creation process encompassing scouting and accelerating high-potential firms through capital provision, resources, and expertise for milestones like patent filings and clinical trials, followed by acquiring controlling stakes for value maximization and premium exits. Founded in 1993 as Cardiotech International, Inc., headquartered in Las Vegas, Nevada, with a former biomaterial development focus now pivoted to life sciences acceleration, it maintains operations blending Nordic innovation and U.S. expertise across the United States and Nordic regions. In March 2023, Nordicus Partners A/S completed a reverse acquisition by EKIMAS, becoming a wholly-owned subsidiary, prompting leadership changes including new board appointments and CEO transition, alongside plans for name change to Nordicus Partners Corporation and ticker shift to NORD, finalized in May 2023; the company further pursued acquisition of remaining Orocidin A/S shares in November 2024 to consolidate holdings.